ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Truckee, CA (UroToday.com) -- Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- Astellas Pharma Inc. and Seattle Genetics, Inc. announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago.
ASCO 2018: Phase III Trial Finds Many People with Advanced Kidney Cancer Do Not Need Surgery
Truckee, CA (UroToday.com) A randomized phase III clinical trial showed that many people with advanced kidney cancer can avoid surgery to remove the kidney (nephrectomy), without compromising survival. The median overall survival for people who received only the targeted therapy sunitinib (Sutent®) was 18.4 months, compared to 13.9 months for those who received surgery followed by sunitinib, the current standard of care.
ASCO 2018: Geriatric Assessment Improves Communication Between Oncologists and Older Patients
Truckee, CA (UroToday.com) -- A federally funded randomized study demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication.
ASCO 2018: Abiraterone May Be More Effective in Black Men with Advanced Prostate Cancer than in White Men
Truckee, CA (UroToday.com) -- In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Zytiga®) was greater and longer lasting in black men than in white men. Black men were more likely to have a decline in prostate-serum antigen (PSA) -- a sign of prostate cancer response -- and had a 5-month longer median time to PSA worsening than white men (16.6 vs. 11.5 months).
ASCO 2018: Black Men with Advanced Prostate Cancer Treated with Chemotherapy May Have Equal or Better Survival than White Men
Truckee, CA (UroToday.com) -- An analysis of pooled data from nine randomized phase III trials of more than 8,000 men with advanced prostate cancer who received chemotherapy shows chances of survival are as good for black men as white men.